Lv1
40 积分 2023-05-29 加入
Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells
9个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
9个月前
已完结
Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer
1年前
已完结
New immune cell engagers for cancer immunotherapy
1年前
已完结
T cell-engaging therapies — BiTEs and beyond
1年前
已完结
Exploring the next generation of antibody–drug conjugates
1年前
已完结
Antibody–drug conjugates come of age in oncology
1年前
已完结
皖公网安备34019202002308
